Pfizer ($PFE) and Novartis ($NVS) have snagged a nod from the CDC's Advisory Committee on Immunization Practices (ACIP) for their recently approved meningitis B vaccines. There's just one problem: It doesn't cover nearly as large a population as the pharma giants would like. Thursday, ACIP voted unanimously to recommend Pfizer's Trumenba and Novartis' Bexsero for use in so-called high-risk groups--namely individuals with immune deficiencies and those in close proximity to ongoing outbreaks. And while both vaccinemakers agree the verdict is a step in the right direction, it's not nearly as broad as their FDA approvals, which cover adults ages 10 to 25. More